Neue Nanoimprint-Anlage von Morphotonics

The exponential growth of miniaturized optical components for a variety of applications demands for robust free-form micro-optics. To address this current market reality, the European PHABULOuS project (Pilot-line providing highly advanced & robust manufacturing technology for optical free-form μ-structures) was launched in January 2020 under CSEM’s leadership with the participation of 19 partners along the manufacturing value chain, including Morphotonics. Installing the large area substrate nano imprinting facility at CSEM by Morphotonics strengthens this endeavor even further.

Dr. Rolando Ferrini (CSEM Sector head & Project Coordinator for PHABULOuS): "CSEM is extremely glad to have found in Morphotonics a competent and highly dedicated partner in rollto- plate (R2P) UV imprint on large area substrates, which substantially complement its long standing competences in wafer scale UV replication. This will enable CSEM to better respond to customer’s requests in large area micro and nano UV replication. In particular, building a close collaboration between Morphotonics and CSEM, as reference Research and Technology Organization (RTO) for the large area R2P manufacturing of next generation free form micro optical components will be an asset for the recently born pilot line for the manufacturing of free form optical micro optics, PHABULOuS, funded under the H2020 framework program."

Dr. Onno Lint (CEO of Morphotonics B.V.): "We are extremely pleased that Swiss top-technology institute CSEM buys Morphotonics' roll-to-plate technology as the new standard in large area nanoimprinting. We look forward to supporting CSEM’s strong expertise in micro-optics, lacquers and applications with our piloting equipment enabling low product cost and high throughput. This opens the door and paves the way for many commercial applications not previously conceptualized or economically feasible, ranging from new display technologies, novel lighting concepts and highly efficient solar solutions to life science products."